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Population Pharmacokinetic/Pharmacodynamic
Modeling of Depot Testosterone Cypionate in Healthy
Male Subjects
Youwei Bi1, Paul J. Perry1,2, Michael Ellerby2 and Daryl J. Murry3*
A randomized, double-blind clinical trial was conducted to investigate long-term abuse effects of testosterone cypionate (TC).
Thirty-one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC.
A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize testosterone concentrations and link
exposure to change in luteinizing hormone and spermatogenesis following long-term TC administration. A linear one-
compartment model best described the concentration-time profile of total testosterone. The population mean estimates for
testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution. Weight, albumin, and their changes from
baseline were identified as significant covariates for testosterone. The estimated potency of total testosterone (tT) with
respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL. Simulation based on the indirect response
model suggests the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis was more severe
and of greater duration in the 250 mg and the 500 mg dose groups.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 259–268; doi:10.1002/psp4.12287; published online 1 March 2018.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Long-term excessive dosing of anabolic steroids can
lead to serious health risks. One of the most significant
physiologic changes induced by the use of testosterone
esters is a dose-dependent impairment of normal tes-
ticular androgen secretion and spermatogenesis.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study characterizes and quantifies changes in
testosterone and LH concentration, and spermatogene-
sis following long-term TC administration.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
 The study developed a PK/PD model based on a ran-
domized three-arm (100 mg, 250 mg, and 500 mg/week)
clinical trial, which quantified the relationship between
testosterone exposure after exogenous administration
and suppression of LH and spermatogenesis. Model
results showed that the suppression of endogenous tes-
tosterone secretion, LH synthesis, and spermatogenesis
was more severe and of greater duration in the 250 mg
and the 500 mg dose groups.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS
 This PK/PD model provides a framework to quantify
and predict the change in LH and spermatogenesis
after exogenous testosterone administration. The aver-
age concentration of tT in the past 18 weeks was found
to have the strongest association with suppression of
spermatogenesis.
Endogenous testosterone is responsible for stimulation and
development of male sex organs and for maintenance of
secondary male characteristics.1 An abnormally low level of
testosterone is referred to as hypoandrogenism, in men it
may result in decreased sex hormone production and defi-
ciency in gamete production and regulation. Depot-
testosterone (testosterone cypionate (TC)) is an oil-soluble
ester of the hormone testosterone and is indicated for
hormone replacement therapy in men who have symptoms
of deficiency or absence of endogenous testosterone.2
It can be used to treat both congenital and acquired
hypoandrogenism.3
Aside from the therapeutic indications, the illegal use of
TC and other anabolic steroids by athletes to gain an unfair
advantage in athletic competitions have been reported for
over 50 years.4–6 Numerous studies have shown that long-
term use or excessive dosing of anabolic steroids can lead
to serious health risks. One physiologic change is a dose-
dependent impairment of normal testicular androgen secre-
tion and spermatogenesis.7–9 This effect is believed to
result from the suppression of circulating luteinizing hor-
mone (LH) and follicle stimulating hormone through a feed-
back loop system of the hypothalamic-pituitary-gonadal
(HPG) axis.9,10 Most studies evaluating anabolic steroid
use are observational and retrospective with studied doses
substantially lower than the dose commonly used by illicit
steroid users.11–14
A randomized, double-blind, placebo-controlled study was
conducted by MacIndoe et al.11 to investigate the effects of
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weekly TC injections upon the HPG axis. Our main objective
of developing a pharmacokinetic/pharmacodynamic (PK/PD)
model based on these data is to characterize and quantify
the effect of long-term administration of supratherapeutic
doses of TC on suppression of LH synthesis and spermato-
genesis. This information may help us better understand the
effect of the illegal use of anabolic steroids on the impair-
ment of testicular androgen secretion.
METHODS
Study design
The study design of the trial has been published else-
where.11 In summary, this is a randomized, double-blind
clinical trial in which 31 healthy male subjects were ran-
domized into the 100 mg/wk (n5 10), 250 mg/wk (n510),
and 500 mg/wk (n5 11) dose groups. The high dosing regi-
mens of 250 mg/week and 500 mg/week resemble doses
illegally used by athletes. The study included two consecu-
tive weekly injections of TC placebo, followed by 14 con-
secutive weekly TC injections. This dosing regimen was
chosen to mimic the common cycling duration observed in
the community.6 After the last weekly injection of active
agent, the subjects received 12 consecutive weeks of TC
placebo injections.
All blood samples were collected between 7 AM and 9 AM.
After the last injection of TC, serum was obtained for total
testosterone (tT) and free testosterone (fT) determinations
at biweekly intervals of 7 days. The tT and fT values mea-
sured in samples drawn immediately postdose, after
8 hours, and then daily for 26 consecutive days after the
last active TC injection were used to determine their elimi-
nation. Biweekly luteinizing hormone releasing hormone
(LHRH) stimulation tests were performed 7 days after the
last injection of either placebo or testosterone to assess
pituitary gonadotropin secretion. Venous blood samples for
LH and follicle stimulating hormone were obtained before
and 30, 60, and 120 minutes after the intravenous infusion
of 100 mcg LHRH. Semen samples were obtained by mas-
turbation at baseline (week 0), and weeks 2, 16, 21, 28,
and, in some subjects, at week 40, and assessed for total
and motile sperm concentrations. Subjects were asked to
be sexually abstinent for 24 hours before sample collection.
Model building
Nonlinear mixed effects modeling was performed using
NONMEM version 7.2. The PK/PD data analysis was per-
formed sequentially. The PK model for tT was first fitted to
the data, and the PD model for suppression of LH synthesis,
and spermatogenesis was then sequentially fitted conditional
on fixed individual PK parameters. Detailed description of
model development, model evaluation, and covariate selec-
tion can be found in the Supplementary Material. A variety
of compartmental models were evaluated with the modeling
attempts to fit the interplay between testosterone and LH
guided by the known physiology in the HPG axis. Potential
covariates (all covariates listed in Table 1) were selected
based on the physiological plausibility and prior knowledge
from published literature. The potential covariates were
tested in a stepwise manner on clearance (CL), volume (V),
Table 1 Baseline demographic characteristics, protein levels, and laboratory test values of 31 healthy volunteers.
Characteristic
Median (range)
100 mg (N510) 250 mg (N5 10) 500 mg (N5 11)
Baseline tT, ng/mL 6.44 (4.04–9.5) 5.93 (4.2–10.6) 5.78 (2.31–9.48)
Baseline fT, ng/dL 2.41 (1.58–4.17) 2.38 (0.28–3.55) 2.44 (1.08–3.09)
Age, years 26.5 (22–32) 25.5 (22–39) 30 (21–39)
Weight, kg 82.2 (61.7–115) 88.8 (61.7–105) 84.7 (60.7–115)
Blood urea nitrogen, mg/dL 14.5 (10–17) 15 (9–18) 15 (8–19)
Serum creatinine, mg/dL 1.05 (0.8–1.5) 1.1 (1–1.2) 1 (0.9–1.2)
Creatinine clearance, mL/min 124 (89.6–179) 123 (90.4–153) 125 (84.3–166)
Albumin, g/dL 4.55 (4.4–6.9) 4.55 (4.3–5.1) 4.6 (1.6–5)
Globulin, g/dL 2.75 (2–3.1) 2.9 (2.4–3.5) 3 (2.8–3.2)
Thyroxine-binding globulin, ug/mL 19.5 (10–31) 18.5 (11–26) 21 (14–26)
Sex hormone-binding globulin, nmol/L 26 (17–46) 24.5 (11–48) 22 (13–47)
Alkaline phosphatase, IU/L 63.5 (52–89) 52 (41–97) 67 (50–98)
Lactate dehydrogenase, IU/L 157 (141–194) 158 (121–196) 143 (111–184)
AST, IU/L 23 (17–32) 20.5 (14–53) 18 (12–34)
ALT, IU/L 22 (16–52) 27.5 (12–47) 19 (10–40)
GGT, IU/L 22 (10–54) 20 (10–54) 18 (10–58)
Total bilirubin, mg/dL 7.25 (6.9–8.1) 7.5 (6.8–8.4) 7.6 (7.1–8)
Direct bilirubin, mg/dL 0.2 (0.2–0.4) 0.25 (0.1–0.4) 0.3 (0.1–0.5)
Triglyceride, mg/dL 110 (40–335) 122 (43–532) 123 (58–538)
Cholesterol, mg/dL 199 (140–238) 184 (139–224) 198 (162–241)
HDL, mg/dL 39 (27–70) 39 (21–54) 33 (22–47)
LDL, mg/dL 125 (65–186) 116 (79–162) 136 (79–181)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipopro-
tein; fT, free testosterone; tT, free testosterone.
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and absorption rate Ka, as implemented in PsN.15 Effect of
covariates was illustrated using simulations that accounted
for parameter precision of fixed effects.
RESULTS
Population pharmacokinetics of testosterone cypionate
Baseline demographic characteristics and laboratory tests
for 31 subjects are summarized in Table 1. Overall, 729 tT
and 379 LH serum samples were available. Among these
observations, 299 tT samples were obtained within 26 days
from the last dose. These samples were used to determine
the main PK parameters.
The data were best fit using a one-compartment model
with linear elimination and first-order absorption. Following
the cessation of TC administration, tT concentrations were
lower than pretreatment concentrations initially and then
slowly returned back to baseline. Initially, the inhibition of
endogenous testosterone was modeled with constant
reduction of its secretion rate in prespecified intervals from
week 4 to week 19 to derive post hoc PK parameters as
inputs for PD model development. The model was then
updated with an indirect maximum effect (Emax) model to
describe the positive regulation of LH on testosterone
secretion. The individual post hoc LH prediction from the
PD model was used in this indirect model because of differ-
ent sampling time of testosterone and LH.
The differential equation describing the testosterone PKs
is shown below:
d ABSð Þ
d tð Þ 52ka  ABS
d Teð Þ
d tð Þ 5bi1ka  ABS2
CL
V
 Te
bi5bbase1Emax 
LHk
LHk1LH50
k
where ka is the first-order absorption rate, and CL and V
are clearance and central volume of distribution. The tT
secretion rate bi is equal to bbase plus upregulation through
LH concentration. The initial condition for Te was estimated
as fixed parameter with random effect during model devel-
opment. The Emax represents the maximum effect of LH on
endogenous testosterone secretion, and LH, LH50, and k
represent LH concentration, the LH concentration when its
upregulation on endogenous testosterone secretion reaches
half of the maximum effect, and hill coefficient.
The final PK parameters for total testosterone are shown
in Table 2. The CL/F and V/F for tT were estimated to be
2.6 (kL/day) and 14.4 kL in healthy men with median
covariate values. The median post hoc half-life was calcu-
lated to be 4.05 days for tT. The Emax and LH50 describing
the positive regulation of LH concentration on the testoster-
one secretion rate were estimated to be 12.5 mg/day and
12.9 IU/L. The estimates of CL and V were insensitive to
the inclusion of LH upregulation on the endogenous secre-
tion rate; the difference in mean post hoc CL and V was
found to be within 20% when compared to the model
without LH upregulation. A combined additive and propor-
tional model was applied to model the residual error.
Significant covariates for tT included baseline weight,
baseline albumin, and change in weight and albumin from
baseline. Power models for baseline weight and albumin,
linear models for change in albumin, and exponential mod-
els for change in weight resulted in the lowest objective
function values (OFVs). The Forest plot of covariate effects
(Figure 1) illustrates that albumin, change in albumin from
baseline, and change in weight from baseline are not clini-
cally important for the testosterone PK parameters, as the
majority of 95% confidence interval (CI) of these covariate
effects fall within the interval of 0.8 to 1.25. On the other
hand, a heavier subject (95th percentile, 110 kg) is esti-
mated to have a 1.23 (95% CI5 1.16–1.32) and 1.58 (95%
CI51.17–2.3) fold higher CL/F and V/F compared to a typi-
cal subject (median5 85 kg), respectively, suggesting
weight had a modest effect on TC PKs. However, consider-
ing the natural variation in testosterone concentrations,
weight-based dosing is not likely to be needed for an i.m.
injection of TC. Of 496 observations for covariates weight,
albumin, and globulin, missing values were replaced by the
previous measurements in 30 (6.05%), 9 (1.81%), and 10
(2.02%) time points, respectively. Basic goodness of fit
(GOF) plots for tT are shown in Supplementary Figure S1.
Prediction-corrected visual predictive checks (VPCs) strati-
fied on dose groups are shown separately for intensive and
Table 2 Population pharmacokinetic parameter estimates and bootstrap
results for total testosterone in 31 healthy volunteers.
Parameter
Final model Bootstrapa
Estimate Median RSE (%) 95% CI
CL/F, kL/day 2.6 2.6 4.53 (2.42–2.8)
V/F, kL 14.4 14.4 12.1 (11.9–17.6)
Ka, day21 1.22 1.22 44.9 (0.785–2.67)
bbase, mg/day 6.24 6.25 23.3 (3.53–8.09)
Lambda kð Þ 1.18 1.43 55.9 (0.43–2.74)
Emax, mg/day 12.5 12.3 25.2 (7.75–18)
LH50, IU/L 12.9 12.7 63.1 (0.892–23.7)
A_0, TC 6.24 6.21 5.82 (5.63–6.85)
hBalbumin2V 21.55 21.84 58.7 (23.56 to 20.842)
hCalbumin2V 20.27 20.27 25.4 (20.369 to 20.108)
hBWT2V 1.71 1.77 36.7 (0.776–2.98)
hBWT2CL 0.785 0.793 17.4 (0.595–1.03)
hCWT2CL 0.016 0.016 45.2 (0.00382–0.0254)
r2 additive 0.261 0.191 105 (0.00261–0.839)
r2 proportional 0.057 0.057 18.7 (0.039–0.073)
IIV_CLb 9.66% (25.2) 8.60% 57.3 (2.98%–12.29%)
IIV_V 37% (14.6) 35.9% 52.8 (18.3%–51.7%)
IIV_Ka 53.9% (42.5) 52.4% 89.7 (0.54%–87.5%)
IIV_Emax 45.3% (16.3) 43.1% 71.6 (14.5%–66.3%)
IIV_k 75.9% (25.3) 72.9% 47.4 (40.0%–99.6%)
IIV_A_0, TC 13.6% (49.6) 13.3% 77.1 (0.14%–21.3%)
CI, confidence interval; CL, clearance; Emax, maximum effect; IIV, inter-
individual variability; RSE%, percentage of relative standard error; TC, tes-
tosterone cypionate; V, volume.
aMedian, RSE, and 95% CIs were calculated based on 500 nonparametric
bootstrap results.
bShrinkage of IIV parameters was reported along with parameter estimates.
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extensive sampling periods in Figure 2. Overall, the GOF
plots and the prediction-corrected VPCs indicated that the
model adequately describes the central tendency and the
variability of the PK profile of testosterone.
Suppression of luteinizing hormone and
spermatogenesis
The PD end point was chosen to be the LH concentration
at 30 minutes after the stimulation test (LH30). An indirect
effect model best described the LH30 observations:
d LH30ð Þ
d tð Þ 5Kin 12INHð Þ2Kout  LH30
INH describes the inhibitory effect of testosterone on LH
synthesis using sigmoid Emax model with effect compart-
ment: INH5Cke/(C
k
e1TC
k
50). The Ce is the hypothetical
effect compartment concentration accounting for the lag
between the increase in testosterone and the loss of LH.
The TC50 is the tT concentration when LH synthesis is
inhibited by half. The Emax is fixed to 1 as LH synthesis is
fully inhibited during the study. The initial condition for LH30
is equal to Kin divided by Kout. The final PD model esti-
mates and covariate-parameter relationships are shown in
Table 3. The TC50 and k were estimated to be 9.33 ng/mL
and 18.3, respectively. Baseline weight and thyroxin were
found to be significant covariates for IC50 and Kin. Based
on the Forest plot of covariate effects shown in Figure 1,
the 95% CI of effects of weight on TC50 and thyroxin on Kin
were almost fully outside of the specified interval 0.8 to
1.25, indicating potential clinical significance. The TC50 of a
heavier subject (95th percentile, 110 kg) is estimated to be
0.74 (95% CI5 0.58–0.91) fold of that of a typical subject
with median weight (85 kg). Simulated LH profiles in sub-
jects with different body weights and thyroxin values are
shown in Supplementary Figure S2. Based on simulation,
LH suppression in volunteers with larger body weight is
estimated to last longer. No difference in simulated LH sup-
pression was identified among volunteers with different thy-
roxin values. Sensitivity analyses were also conducted to fit
the same indirect response model to end points LH60 and
LH120. All models had similar parameter estimation and
comparable performance.
Semenogram data were available in 29 subjects, with two
subjects not providing sample due to vasectomies. A total
of 159 sperm samples were obtained over the 40 weeks of
study. A total of 11 subjects missed 15 of 174 (8.6%)
planned visits for collection of sperm samples; 7 subjects
(24.1%) missed the sample collection at the end of the
study, which might bias the estimate of suppression level of
spermatogenesis at that time point. Because there is a very
high correlation between sperm count and sperm motility
(adjusted R250.87), the sperm count was used as the
main PD end point. An indirect effect model best described
the sperm counts over time, the differential equation of
which is the same as the indirect model used to fit LH sup-
pression. The average tT concentration across different
time periods (from Cavg since the beginning to Cavg in the
past week) preceding each observation were selected to
Figure 1 Effect of baseline and time-varying covariates on pharmacokinetic parameters (clearance (CL) and volume (V)) and pharma-
codynamic parameters for suppression of luteinizing hormone (half-maximal inhibitory concentration (IC50), Kin) and spermatogenesis
(Cavg50). Error bars indicate 95% confidence interval based on a nonparametric bootstrap.
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represent testosterone exposure and its associations with
suppression of spermatogenesis. The inhibition of testoster-
one dosing on spermatogenesis over time was best described
by an indirect sigmoid Emax model without effect compart-
ment: INH512EmaxCavgk= Cavgk1Cavgk50
 
. Cavg in the
past 18 weeks (Cavg_18 weeks) was found to best describe
the effect of exogenous testosterone administration on sup-
pression of spermatogenesis (with lowest OFV). The
Cavg_18 weeks for semen data measured at a time <18
weeks (baseline and between 2 and 16 weeks) is the average
concentration from beginning to the time of measurement.
Logistic transformation was applied on Emax in order to con-
strain its value between 0 and 1: Emax5
exp PHIð Þ
11exp PHIð Þ : An additive
error model was applied to PHI, and exponential error models
were applied to Kin, k; and Cavg50: A sensitivity analysis
using sperm motility as the PD end point with the same indi-
rect response model was also conducted and had similar
parameter estimation and comparable performance. Final PD
model estimates for suppression of sperm counts and sperm
motility are shown in Table 3 and Supplementary Table S1.
Cavg50 was estimated to be 8.68 ng/mL. Baseline weight was
found to be a significant covariate for Cavg50. The Cavg50 of
Figure 2 Prediction-corrected visual predictive check for total testosterone obtained from 1,000 simulations stratified on dose and sam-
pling period. Black solid points are observed concentrations. Red solid and dashed lines represent 2.5th, 50th, and 97.5th percentiles
of observed data. The shaded areas indicate simulation-based 95% confidence intervals around the median (orange) and the 2.5th
and 97.5th percentiles (blue) from 1,000 simulations with the final model. Note: All subjects received 14 weekly injections of testoster-
one cypionate (TC) from week 2 to week 15. Intensive pharmacokinetic sampling was collected immediately postdose, at 8 hours, and
then daily for 26 consecutive days after the last active TC injection (week 15).
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a heavier subject (95th percentile, 110 kg) was estimated to
be 0.72 (95% CI5 0.55–0.91) fold of that of a typical subject
with median weight (85 kg).
Basic GOF plots were plotted against observations of LH
and sperm counts and motility in Supplementary Figure S3.
The visual predictive checks (VPC) for LH and sperm counts
are shown in Figure 3. Overall, diagnostic plots show that
indirect response models were able to describe the suppres-
sion of LH synthesis and spermatogenesis after long-term
dosing of TC.
The magnitude and variability of suppression of LH and
sperm counts based on post hoc parameters at each dose
level were summarized and shown in Figure 4. Both the
observed data (black dots) and suppression level generated
from post hoc parameters (colored line and areas) suggest
the suppression of LH was more severe in the 250 mg and
the 500 mg groups, whereas the suppression is variable in
the 100 mg group. The median suppression level for the
100 mg group was >90% and has a wide CI during 14
weeks of active TC dosing. On the other hand, the lower
bound of 90% CI of suppression level was higher than 98%
from week 7 to week 16 in the 250 mg group and from
week 12 to week 17 in the 500 mg group. The recovery of
suppression of LH synthesis was also found to be slower in
the 500 mg group compared to the 250 mg and the
100 mg groups. The median suppression level dropped to
below 10% in week 10 after the last testosterone adminis-
tration in the 500 mg group, compared after week 5 in the
100 mg group and week 6 in the 250 mg group.
Similarly, the suppression of sperm counts was much
more severe in the high dose groups (Figure 4). At the end
of 14 weeks of TC dosing, the sperm count was found to
be completely suppressed in both the 250 mg and the
500 mg groups. The median suppression level at week 15
in the 250 mg and the 500 mg groups were simulated to be
98.2% and 94.9%, respectively. The recovery of sperm
secretion (Kin) also seems to be slower in the higher dose
group, with the median suppression level estimated to be
66.9% for 500 mg group, 48.4% for 250 mg group, and
26.6% for the 100 mg group at week 28, respectively. At
the end of the study period (week 40) the sperm secretion
(Kin) almost returned to normal in the 100 mg and the
250 mg groups, but the sperm counts in some subjects are
still lower than baseline values (suppression level5 24.0;
95% CI5 0–67%). As there were 7 subjects (24.1%) who
missed the semen collection at the end of the study, a sen-
sitivity analysis including 22 subjects with complete data
only was conducted, and parameter estimates were very
similar (data not shown).
DISCUSSION
Following the depot administration of TC, the PKs of tT
were satisfactorily described by the one-compartmental
model with first-order absorption. The limited number of
samples in the absorption phase (1–2 samples per subject)
prevents using a more plausible absorption model for the
high lipophilicity of testosterone in an oil base and adminis-
tered i.m., such as a mixed zero-order and first-order model
with lag time.16 This could lead to flip-flop PKs and can
cause difficulties in estimation and interpretation of PK
parameters.17 The half-life of testosterone undecanoate
(TU) following oral administration is around 150 minutes,18
which is very different from the half-life estimate of 21–34
days following the i.m. injection of TU reported by Behre
et al.19 The large difference in half-lives of TU between oral
and i.m. formulation suggests that flip-flop PKs are occurring
with testosterone esters, which is also reported in the pub-
lished literature20 and for the i.m. injection of nandrolone.21
The i.m. injection of TC is also likely to have flip-flop kinetics,
in such a scenario, diffusion and release from an oily depot
site is the rate-limiting step to systemic availability.
Endogenous testosterone secretion was described by the
combination of basal testosterone secretion and positive
regulation by LH. The LH stimulates Leydig cell production
of testosterone. The interplay between LH and testosterone
after treatment with gonadotropin-releasing hormone (GnRH)
agonists and antagonists has also been described previ-
ously.22 The positive regulation of LH was completely sup-
pressed between week 13 and week 17 for the 100 mg
group and between week 7 and week 19 for the 250 mg
and the 500 mg dose groups, which is consistent with the
Table 3 Population pharmacodynamic estimates and bootstrap results of
suppression of LH synthesis and sperm count following long-term dosing of
testosterone cypionate in 31 healthy volunteers.
Parameter
Final model
Bootstrapa
estimate Median RSE (%) 95% CI
LH
Kin, IU/day 1.7 1.7 14.4 (1.36–2.16)
Kout, L/day 0.11 0.11 10.8 (0.093–0.133)
Test50; ng/mL 9.33 9.35 5.62 (8.55–10.1)
Lambda; k 18.3 18.7 21.6 (13.6–27.3)
ke0; mL/day 0.0321 0.0318 11.2 (0.0261–0.0377)
r2 additive 0.397 0.395 10.8 (0.331–0.463)
hBwt2IC50 21.14 21.13 38.9 (21.88 to 20.494)
hBthyroxin2Kin 1.19 1.22 27.1 (0.916–1.96)
IIV_Kinb 39.2% (14) 37.6% 51.4 (21.5%–52.4%)
IIV_IC50 27.7% (53.5) 27.1% 32.2 (19.0%–33.3%)
IIV_k 42.2% (7.2) 38.0% 103 (0.42%–71.6%)
IIV_ke0 46.6% (0.5) 45.2% 43.7 (31.1%–64.3%)
Sperm count
Kin,/day 6.17 6.40 58.5 (4.92–9.02)
Kout,/day 0.0696 0.0714 59.3 (0.0616–0.0966)
Cavg50; ng/mL 8.68 8.74 10.5 (7.3–10.3)
Lambda; k 11.3 11.7 31.5 (6.89–19.7)
Phi /ð Þ 4.65 4.58 19.2 (3.67–6.47)
hBwt2Cavg50 21.27 21.25 37.5 (22.06 to 20.536)
r2 additive 0.429 0.421 19 (0.311–0.56)
IIV_Kin
b 46.8% (14.2) 45.8% 35.2 (31.6%–59.3%)
IIV_Phi /ð Þ 234% (35.9) 214% 73.6 (110%–377%)
IIV_Cavg50 23.2% (18.6) 22.4% 57.4 (9.33%–31.53%)
IIV_k 100% (28.9) 98.3% 60.6 (63.8%–159.7%)
CI, confidence interval; LH, luteinizing hormone; RSE%, percentage of rela-
tive standard error.
aMedian, RSE, and 95% CIs were calculated based on 500 nonparametric
bootstrap results.
bShrinkage of IIV parameters was reported along with parameter estimates.
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clinical observation that it took shorter time to observe the
loss of basal and LHRH-stimulated LH in the 250 mg and
the 500 mg groups. The mean post hoc endogenous tes-
tosterone secretion rate at baseline in PK models for tT
models was 12.5 mg/day. It is suggested that men produce
between 4 and 11.8 mg of testosterone per day,23 which is
slightly lower than our model estimate. However, there is
wide variability in normal testosterone concentrations with
ranges reported between 300 and 1,000 ng/dl,24 our model
estimates of endogenous testosterone secretion rate are
consistent with reported values and close to reported physi-
ological values. The endogenous testosterone secretion
rate over time is presented in Figure 4. Inhibition of endog-
enous secretion lasted longer and was more severe in the
250 mg and the 500 mg groups. The upregulation of LH on
endogenous testosterone secretion was completely lost dur-
ing week 9 to week 19 in both the 250 mg and the 500 mg
groups. The endogenous testosterone secretion rate
returned to baseline at approximately week 23 in all three
dose groups. The parameter estimates (LH50512.9 IU/L;
Emax512.5) of downregulation of endogenous testosterone
through inhibition of LH was slightly different from those
reported by Tornøe et al.22 (LH5055.18 IU/L; Emax5 77.5),
but they are not directly comparable because we use differ-
ent differential equation to fit the interplay between LH and
testosterone secretion.
Inclusion of time-varying covariates besides resulted in
lower interindividual variability on the main PK tT parameters.
However, changes in weight and albumin concentrations
were likely not clinically significant. Analysis of covariate
effects suggests baseline weight is the only potential covari-
ate of clinical importance for the PKs of TC.
It is difficult to calculate the PK parameters of TC using
traditional noncompartmental methods, especially when the
endogenous testosterone secretion rate is suppressed dur-
ing the course of TC administration and the testosterone
secretion rate is regulated by the LH-testosterone feedback
loop system in HPG axis. Our estimated post hoc median
tT half-life was 4.05 days, which is shorter than the mean
reported elimination half-life of 6.9 days determined using a
noncompartmental analysis.11 Such inconsistency is
believed to result from failure to consider endogenous tes-
tosterone production. When we assume endogenous tes-
tosterone secretion is 0 in the PPK analysis, the median
estimated half-life increases to 6.87 days.
There are no population PK data available for the long-
term supratherapeutic administration of testosterone ester.
The developed model-based PPK approach allowed us to
estimate endogenous testosterone production rate during
and after TC administration.
After characterizing the PKs of long-term TC dosing in
healthy male subjects, the PD model was sequentially
developed. An indirect response model was used to
describe the change of LH30 during and after TC dosing.
The LH concentration after a stimulation test was chosen
as the PD marker in part because the response of LH to
Figure 3 Visual predictive checks for luteinizing hormone (left) and sperm counts (right) obtained from 1,000 simulations. Black solid
points are observed concentrations. Red solid and dashed lines represent 2.5th, 50th, and 97.5th percentiles of observed data. The
shaded areas indicate simulation-based 95% confidence intervals around the median (orange) and the 2.5th and 97.5th percentiles
(blue) from 1,000 simulations with the final model.
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the stimulation test was different across all three TC dose
groups. The lag between loss of basal and stimulated LH
levels has been previously observed.25 The ability of exoge-
nous testosterone administration to suppress LH release
was incorporated into the PD model. A sigmoid Emax model
was applied to link testosterone concentrations with its
inhibitory effect on LH synthesis. The addition of an effect
compartment accounted for the lag between loss of LH and
the increase in testosterone concentration.
We developed a PD model to describe the inhibition of
spermatogenesis during TC dosing and the subsequent
recovery. The effect of average tT concentration during dif-
ferent dosing intervals preceding each sperm observation
was tested on spermatogenesis in the indirect sigmoid
Emax model. The average testosterone concentration in the
past 18 weeks preceding each observation was found to
result in the lowest OFV. The effect of tT Cavg across
different time periods on suppression of sperm counts was
also tested. Bias in VPC and simulation results was identi-
fied using exposure metrics with shorter observation peri-
ods than 14 weeks. The requirement of long-time PK
measurement preceding each semen data aligns well with
the clinical observation that suppression level of spermato-
genesis at 13 weeks after the last active TC administration
was still high in both the 250 mg and 500 mg dose groups,
although it may limit the practical applicability of the model.
To the best of our knowledge, this is the first time the rela-
tionship between testosterone exposure after exogenous
administration and suppression of spermatogenesis has
been quantified. The Cavg of testosterone in the past 18
weeks was found to have the strongest association with
suppression of spermatogenesis and also provided informa-
tion regarding the duration of effect of TC administration on
spermatogenesis.
Figure 4 Summary of level of suppression of endogenous testosterone secretion (top), luteinizing hormone synthesis (LH; middle), and
sperm counts (bottom) over time during and after testosterone cypionate dosing based on post hoc parameters from 31 subjects. Col-
ored solid lines represent the median suppression level. Horizontal dashed line represents basal endogenous testosterone secretion
independent of LH upregulation. Shaded areas indicate 95% confidence interval of the suppression level. Blue: 100 mg, Red: 250 mg,
and Green: 500 mg. Black solid points represent the observed percentage change of variable of interest (LH30 or sperm counts) from
baseline. The size of black points represents the frequency of observations.
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Most studies evaluating abuse effects of androgen ste-
roids are observational studies and study designs are often
not randomized, double-blind, or placebo-controlled. Sub-
jects are usually exposed to a dose much lower than what
is commonly used by illicit steroid users and administered
for only a short period. The untoward effects of anabolic
steroids on a healthy body, therefore, may be underesti-
mated in the literature. To best of our knowledge, this is the
first time a mechanistic population PK/PD model has been
developed to quantify the relationship between testosterone
exposure after exogenous administration and subsequent
suppression of LH and spermatogenesis during and after
long-term supratherapeutic administration of testosterone
ester in healthy subjects. Tornøe et al.22 developed a PK/
PD model of HPG axis describing the changes in LH and
testosterone concentrations after treatment with GnRH ago-
nist triptorelin and GnRH receptor blocker degarelix. Pech-
stein et al. adequately described the PK/PD relationship
between plasma levels of Cetrorelix and testosterone sup-
pression following a single i.v. and s.c. dosing. However,
only one single i.v. or s.c. administration was given to
healthy subjects in both studies and neither captured the
change in spermatogenesis. The proposed PK/PD model
in our analysis allows for the quantification and compari-
son of the suppression of LH synthesis and spermatogen-
esis at various time points during and after administration
of exogenous testosterone esters. We were also able
to extrapolate the recovery of LH secretion and spermato-
genesis in future time points based on post hoc
parameters.
One limitation of the current study is PPK model was
developed based on the data from 31 healthy subjects, the
precision of estimated covariate effects (Figure 1) was
expected to be relatively low due to the small sample size.
Re-estimation of the PK parameters may be necessary if
the current PPK model is going to be applied to the patient
population. A series of physiological changes in renal func-
tion, body composition, or protein concentrations is likely to
affect the binding affinity of testosterone as well as the PK
profile of exogenous testosterone administration in the
elderly patients.26,27 Certain patient populations may also
have lower levels of endogenous testosterone secretion,
and altered bbase compared with our model estimates. The
small sample size (N5 31) may limit the precise estimation
of suppression level of LH and spermatogenesis. The LH
suppression for the 250 mg and 500 mg doses during TC
administration were consistent and severe, whereas it was
variable for the 100 mg dose. The variability of LH recovery
after TC administration was large in all three groups. Simi-
larly, for spermatogenesis, suppression at week 15 and
week 21 were precisely estimated but recovery was esti-
mated with wide CIs. The study design did not follow sub-
jects long enough to allow observation of complete
recovery from inhibition of spermatogenesis, which may
have contributed to the high uncertainty in the estimates of
Kin and Kout.
In summary, we developed a PK/PD model to charac-
terize the PK profile of tT following long-term weekly
injection of TC, and linked testosterone exposure to the
PD effects, including suppression of LH synthesis and
spermatogenesis and their recovery during TC dosing in
healthy men. Our model supports the finding that the
suppression of endogenous testosterone secretion, LH
synthesis, and spermatogenesis is more severe and of
greater duration in subjects receiving higher TC doses.
Source of Funding. This project was supported by a grant from the
National Institute on Drug Abuse at the National Institutes of Health
R01DA008347.
Conflict of Interest. The authors declared no conflict of interest.
Author Contributions. Y.B. and D.J.M. wrote the manuscript. P.P.
designed the research. P.P. performed the research. Y.B., M.E., and
D.J.M. analyzed the data.
1. Brinkmann, A.O. Molecular basis of androgen insensitivity. Mol. Cell. Endocrinol. 179,
105–109 (2001).
2. Sih, R., Morley, J.E., Kaiser, F.E., Perry, H.M. 3rd, Patrick, P. & Ross, C. Testoster-
one replacement in older hypogonadal men: a 12-month randomized controlled trial.
J. Clin. Endocrinol. Metab. 82, 1661–1667 (1997).
3. Matsumoto, A.M. Hormonal therapy of male hypogonadism. Endocrinol. Metab. Clin.
North Am. 23, 857–875 (1994).
4. Sj€oqvist, F., Garle, M. & Rane, A. Use of doping agents, particularly anabolic ste-
roids, in sports and society. Lancet 371, 1872–1882 (2008).
5. Perry, P.J., Andersen, K.H. & Yates, W.R. Illicit anabolic steroid use in athletes. A
case series analysis. Am. J. Sports Med. 18, 422–428 (1990).
6. Strauss, R.H. & Yesalis, C.E. Anabolic steroids in the athlete. Annu. Rev. Med. 42,
449–457 (1991).
7. Matsumoto, A.M. Effects of chronic testosterone administration in normal men: safety
and efficacy of high dosage testosterone and parallel dose-dependent suppression of
luteinizing hormone, follicle-stimulating hormone, and sperm production. J. Clin. Endo-
crinol. Metab. 70, 282–287 (1990).
8. Hartgens, F. & Kuipers, H. Effects of androgenic-anabolic steroids in athletes. Sports
Med. 34, 513–554 (2004).
9. Evans, N.A. Current concepts in anabolic-androgenic steroids. Am. J. Sports Med.
32, 534–542 (2004).
10. Jarow, J.P. & Lipshultz, L.I. Anabolic steroid-induced hypogonadotropic hypogonad-
ism. Am. J. Sports Med. 18, 429–431 (1990).
11. MacIndoe, J.H., Perry, P.J., Yates, W.R., Holman, T.L., Ellingrod, V.L. & Scott,
S.D. Testosterone suppression of the HPT axis. J. Investig. Med. 45, 441–447
(1997).
12. Swerdloff, R.S., Palacios, A., McClure, R.D., Campfield, L.A. & Brosman, S.A. Male
contraception: clinical assessment of chronic administration of testosterone enanthate.
Int. J. Androl. 1, 731–747 (1978).
13. Perry, P.J., Yates, W.R. & Andersen, K.H. Psychiatric symptoms associated with ana-
bolic steroids: a controlled, retrospective study. Ann. Clin. Psychiatry 2, 11–17
(1990).
14. Yates, W.R., Perry, P. & Murray, S. Aggression and hostility in anabolic steroid
users. Biol. Psychiatry 31, 1232–1234 (1992).
15. Jonsson, E.N. & Karlsson, M.O. Automated covariate model building within NON-
MEM. Pharm. Res. 15, 1463–1468 (1998).
16. Samtani, M.N., Vermeulen, A. & Stuyckens, K. Population pharmacokinetics of intra-
muscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly,
long-acting formulation of an atypical antipsychotic. Clin. Pharmacokinet. 48, 585–600
(2009).
17. Ya~nez, J.A., Remsberg, C.M., Sayre, C.L., Forrest, M.L. & Davies, N.M. Flip-flop
pharmacokinetics–delivering a reversal of disposition: challenges and opportunities
during drug development. Ther. Deliv. 2, 643–672 (2011).
18. Sch€urmeyer, T., Wickings, E.J., Freischem, C.W. & Nieschlag, E. Saliva and serum
testosterone following oral testosterone undecanoate administration in normal and
hypogonadal men. Acta Endocrinol. (Copenh.). 102, 456–462 (1983).
19. Behre, H.M., Abshagen, K., Oettel, M., H€ubler, D. & Nieschlag, E. Intramuscular
injection of testosterone undecanoate for the treatment of male hypogonadism: phase
I studies. Eur. J. Endocrinol. 140, 414–419 (1999).
20. Moeller, B.C., Sams, R.A., Guinjab-Cagmat, J., Szabo, N.J., Colahan, P. & Stanley,
S.D. An interlaboratory study of the pharmacokinetics of testosterone following intra-
muscular administration to thoroughbred horses. J. Vet. Pharmacol. Ther. 34,
588–593 (2011).
21. Bagchus, W.M., Smeets, J.M., Verheul, H.A., De Jager-Van Der Veen, S.M., Port, A.
& Geurts, T.B. Pharmacokinetic evaluation of three different intramuscular doses of
PK/PD Modeling of Depot Testosterone Cypionate
Bi et al.
267
www.psp-journal.com
nandrolone decanoate: analysis of serum and urine samples in healthy men. J. Clin.
Endocrinol. Metab. 90, 2624–2630 (2005).
22. Tornøe, C.W. et al. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling
of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.
Br. J. Clin. Pharmacol. 63, 648–664 (2007).
23. Korenman, S.G., Wilson, H. & Lipsett, M.B. Testosterone production rates in normal
adults. J. Clin. Invest. 42, 1753–1760 (1963).
24. Goldman, L. & Schafer, A. The testis and male sexual function. (eds. Goldman, L. &
Schafer, A.I.). Goldman’s Cecil Medicine 24th Edition (Saunders Elsevier, Philadel-
phia, PA, 2011).
25. Caminos-Torres, R., Ma, L. & Snyder, P.J. Testosterone-induced inhibition of the LH
and FSH responses to gonadotropin-releasing hormone occurs slowly. J. Clin. Endo-
crinol. Metab. 44, 1142–1153 (1977).
26. Mangoni, A.A. & Jackson, S.H. Age-related changes in pharmacokinetics and phar-
macodynamics: basic principles and practical applications. Br. J. Clin. Pharmacol. 57,
6–14 (2004).
27. Vermeulen, A., Kaufman, J.M. & Giagulli, V.A. Influence of some biological indexes
on sex hormone-binding globulin and androgen levels in aging or obese males. J.
Clin. Endocrinol. Metab. 81, 1821–1826 (1996).
VC 2018 The Authors CPT: Pharmacometrics & Systems
Pharmacology published by Wiley Periodicals, Inc. on
behalf of American Society for Clinical Pharmacology and
Therapeutics. This is an open access article under the
terms of the Creative Commons Attribution-
NonCommercial License, which permits use, distribution
and reproduction in any medium, provided the original
work is properly cited and is not used for commercial
purposes.
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website
(http://psp-journal.com)
PK/PD Modeling of Depot Testosterone Cypionate
Bi et al.
268
CPT: Pharmacometrics & Systems Pharmacology
